Will US FDA User Fee Reauthorization Bring More RATS?
Executive Summary
Congress should broaden scope of the 21st Century Cures’ regenerative advanced therapies (RAT) program to include gene therapies and other innovative treatments for rare diseases, attorney Sasinowski says, suggesting such an expansion could be part of the PDUFA legislation.
You may also be interested in...
Crackdown On Bad Regenerative Medicine Actors By US FDA Could Benefit Honest Developers
The agency plans to offer a series of guidance documents on regenerative product development as enforcement against "unscrupulous actors" continues.
Crackdown On Bad Regenerative Medicine Could Benefit Gene Therapy
US FDA to offer series of guidances on regenerative product development – and declares gene therapies eligible for RMAT – as enforcement against 'unscrupulous actors' continues.
Regenerative Medicines Provisions Of Cures Act A Top Priority For CBER
CBER Director Peter Marks says center will mobilize necessary resources to make sure these provisions are implemented; Marks also offered comments in opposition to 'right-to-try' legislation.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: